Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study
Authors' conclusion
SPNM occurred more frequently in anti-MDA5 antibody-positive than in anti-MDA5 antibody-negative myositis patients. SPNM occurrence was associated with higher mortality risk, especially in anti-MDA5 antibody-positive patients.
Study context
- Population
- DM/PM patients with interstitial lung disease (ILD) hospitalised at five Japanese hospitals, 2016–2020119 analysed
- Participants
- 119 patients
- Exposure
- Spontaneous pneumomediastinum (SPNM) vs non-SPNM
- SPNMn = 23
- Outcome
- Death within 1 year from therapy initiation or strengthening
- Follow-up
- 1 year
Methodological detailsmulticentre (five Japanese hospitals)
- Multicentre (five Japanese hospitals)
Main finding
As reported in the abstract
Mortality
P = 0.001
Observational data: associations, not effects.
Further findings
Mortality in anti-MDA5 antibody-positive patients (subgroup) · 1 year
P = 0.001
- Mortality in anti-MDA5 antibody-positive patients (subgroup): All SPNM deaths in anti-MDA5-positive patients (8/15); none of anti-MDA5-negative SPNM patients died (0/8)
Original publication
Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study. RMD Open. Published 9 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →